Xuefei Zhong

Principal Scientist Regeneron Pharmaceuticals

Seminars

Monday 3rd November 2025
Understanding LC-MS Based Bioanalysis Approaches to Determine REGN5093-M114 DAR in Clinical PK Samples
1:30 pm
  • Introducing REGN5093-M114 ADC with M114 linker-payload and bispecific antibody targeting two MET epitopes
  • Outlining exploratory objective of first-in-human study to assess DAR changes in patient plasma samples following intravenous administration
  • Developing LC-MRM-MS based assays to monitor average DAR changes and an IP-intact MS method to characterize payload distribution in PK samples
Xuefei Zhong - 16th World ADC San Diego